Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001060998 | SCV001225720 | uncertain significance | Bloom syndrome | 2025-01-21 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 126 of the BLM protein (p.Pro126Ala). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BLM-related conditions. ClinVar contains an entry for this variant (Variation ID: 133709). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003352773 | SCV004072632 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-03-19 | criteria provided, single submitter | clinical testing | The c.376C>G (p.P126A) alteration is located in exon 3 (coding exon 2) of the BLM gene. This alteration results from a C to G substitution at nucleotide position 376, causing the proline (P) at amino acid position 126 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
ITMI | RCV000120238 | SCV000084386 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Natera, |
RCV001060998 | SCV001456639 | uncertain significance | Bloom syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |